Abstract：
As genomic medicine advances, opportunities for molecular pathology diagnosis by pathologists to be used as companion diagnostics is increasing. Pathological specimens must be useful not only for pathological diagnosis, but also for genetic testing panel and molecular pathology diagnosis. Companion diagnostics performed by pathologists uses immunohistochemical staining and fluorescence in situ hybridization to determine patient eligibility for molecular target drugs and immune checkpoint inhibitors. By accurately observing a wide variety of diagnostic criteria and performing with high precision, pathological diagnosis will become closer to therapeutic pathology.
摘要：
随着基因组医学的进步，病理学家将分子病理学诊断用作伴随诊断的机会正在增加。病理标本必须不仅对病理诊断有用，还用于基因检测小组和分子病理学诊断。病理学家进行的伴随诊断使用免疫组织化学染色和荧光原位杂交来确定患者对分子靶标药物和免疫检查点抑制剂的资格。通过准确地观察各种诊断标准并以高精度执行，病理诊断将更接近治疗病理学。
